FOR IMMEDIATE RELEASE

TriAltus Bioscience Extends Patent Protection for CLīM Protein Purification Technology

BIRMINGHAM, Ala., August 20, 2024 -- TriAltus Bioscience announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12030913 for its innovative CL7/Im7, branded as “CLīM”, technology.

The patented "Bacterial Colicin-Immunity Protein Purification System" features an engineered Colicin Immunity protein (Im7) designed to enhance binding and stability. Im7 is integral to the CLīM protein purification system, where it can be immobilized on solid supports or substrates for diverse applications. CLīM utilizes the high affinity between the engineered CL7 affinity tag and Im7 ligand to achieve highyield, high-purity protein purification, addressing limitations seen in other affinity systems.

The technology has been licensed from the University of Alabama at Birmingham, where Dmitry Vassylyev, Ph.D., professor of biochemistry and molecular genetics, led the invention efforts.

CEO Bob Shufflebarger commented, “This patent reinforces the foundational technology that enables TriAltus to produce and market engineered enzymes of exceptional quality and value. We anticipate that enhancing the value proposition for end-users will drive market expansion, influencing procurement decisions within the life science and biotech sectors, thereby allowing them to focus on discovery and development.”

“The new patent is the second U.S. patent issued for Dr. Vassylyev’s innovative protein purification technology,” said Kathy Nugent, Ph.D., Executive Director of UAB’s Harbert Institute for Innovation and Entrepreneurship. "Protein purification is vital to biotechnological processes, and this method is inexpensive yet efficient. We are proud that this UAB-developed technology may, in turn, drive new innovation in biotechnology."

About TriAltus Bioscience

TriAltus Bioscience harnesses its proprietary CLīM affinity purification system to deliver proteins with exceptional purity and yield, streamlining the production process. TriAltus has demonstrated the effectiveness of its technology on a variety of complex proteins and is now forming strategic partnerships to apply its systems to bespoke customer projects.

For more information, visit Protein Purification Simplified – TriAltus Bioscience

Contact:

Tessa Blackburn

Director, Business Development TriAltus Bioscience

tessa.blackburn@trialtusbioscience.com

+1 (205) 453-8242